Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Serina Therapeutics ( (SER) ) has provided an update.
On October 6, 2025, Serina Therapeutics announced the receipt of the first $5 million funding tranche from a $20 million financing agreement to support the registrational trial of SER-252 for advanced Parkinson’s disease. The company has submitted an IND to the FDA and received HREC approval in Australia, with the trial set to begin in Q4 2025, marking a significant step in addressing unmet needs for Parkinson’s patients.
The most recent analyst rating on (SER) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
Serina Therapeutics’ overall stock score is primarily impacted by its poor financial performance, characterized by significant losses, high liabilities, and negative cash flow. The technical analysis presents a neutral outlook with no strong trend, while the valuation is unattractive due to a negative P/E ratio and lack of dividend yield. These factors collectively suggest a high-risk investment with potential for further decline unless substantial improvements are made.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug product candidates for neurological diseases and other indications using its proprietary POZ Platform™. The company is headquartered in Huntsville, Alabama, and aims to improve the efficacy and safety profiles of various therapeutic modalities.
Average Trading Volume: 123,566
Technical Sentiment Signal: Sell
Current Market Cap: $53.66M
See more data about SER stock on TipRanks’ Stock Analysis page.